We are monitoring the impact of COVID-19 on North America Cancer Immunotherapy Market Get in touch with us for detailed analysis Know More
Share on

North America Cancer Immunotherapy Market Research Report – Segmented By Application, Product Type, Mode Of Administration, End Users, Country (United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1337
Pages: 132

North America Cancer Immunotherapy Market Size (2022 to 2027)

The size of the cancer immunotherapy market in North America is estimated to be USD 28.30 Billion in 2022 and USD 50.32 Billion by the end of 2027, growing at a CAGR of 12.2% from 2022 to 2027.

Cancer has been the primary concern for North America over the years; therefore, the increasing prevalence of cancer is majorly driving the market growth in North America. Also, the growing patient population suffering from various diseases such as lung cancer, breast cancer, ovarian cancer, and other cancers are driving the global cancer immunotherapy market. 

The other factors such as advancing healthcare infrastructure, increasing healthcare spending, and access to medical insurance in the developed countries such as U.S. and Canada are further influencing the market growth. In addition, the adoption of advanced technology in cancer treatment in hospitals is more likely to increase the market growth during the forecast period. Over the years, in the developed countries such as the United States, the demand for cancer immunotherapy has increased significantly owing to its beneficial factors such as minor side effects, long-term cancer protection; moreover, it treats a wide range of cancer populations. 

On the other hand, growing awareness among people about cancer prevalence and the availability of cancer treatments is likely to uplift the market growth. Furthermore, in North America, cancer immunotherapy has emerged as a new source of income for pharmaceutical firms. As a result, various companies and pharmaceutical firms conduct research and development activities that are expected to provide lucrative growth opportunities to the market. 

Moreover, increasing investment and funding by the government and private organizations for creating awareness programs among the people in the region about cancer treatment and availability of advanced treatment is expected to propel the market growth. Furthermore, New immunotherapy drugs are being approved for various diseases, including lung cancer, prostate cancer, blood cancer, colorectal cancer, melanoma, breast cancer, and others, which is driving the industry forward.

However, the high cost of cancer therapies, limited information on cancer immunotherapy, and stringent government policies on immunotherapy in some countries hinder the market growth. 

This research report on the North American Cancer Immunotherapy market has been segmented & sub-segmented into the following categories:

By Type of Therapies: 

  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies

By Area of Therapy: 

  • Blood Cancer
  • Prostate Cancer
  • Melanoma
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other Minor Areas

By Country: 

  • The United States
  • Canada
  • Rest of North America

Geographically, the North American market held the largest share in the global cancer immunotherapy market in 2020, attributed to the major contribution from the United States. The increasing number of cancer patients, sophisticated medical infrastructure, continuous research and development activities, and the availability of product manufacturers are the main aspects supporting the United States cancer immunotherapy market, which further boosts the North American market growth.

On the other side, the Canadian cancer immunotherapy market is forecasted to register a healthy growth rate from 2022 to 2027.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the North America cancer immunotherapy Market profiled in this report are F. Hoffmann-La Roche Ltd, Amgen, Viralytics, Novartis Pharmaceuticals Corporation, Pfizer, GlaxoSmithKline Pharmaceuticals Limited, AstraZeneca plc, Medivation, Advaxis, Bristol-Myers Squibb, Merck & Co. and Celgene Corp and Immunomedics.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Application                 

                                5.1.1 Introduction           

                                5.1.2 Breast       

                                5.1.3 Lung          

                                5.1.4 Melanoma              

                                5.1.5 Colorectal

                                5.1.6 Head & Neck          

                                5.1.7 Prostate   

                                5.1.8 Others      

                                5.1.9 Y-o-Y Growth Analysis, By Application         

                                5.1.10 Market Attractiveness Analysis, By Application     

                                5.1.11 Market Share Analysis, By Application      

                5.2 Product Type                             

                                5.2.1 Introduction           

                                5.2.2 Monoclonal Antibodies     

                                5.2.3 Checkpoint inhibitors/immune modulators              

                                5.2.4 Therapeutic cancer vaccines            

                                5.2.5 Oncolytic virus immunotherapy     

                                5.2.6 Cytokines

                                5.2.7 Adoptive T cell transfer     

                                5.2.8 Adjuvant Immunotherapy

                                5.2.9 Interferons             

                                5.2.10 Interleukins         

                                5.2.11 BCG         

                                5.2.12 Others   

                                5.2.13 Y-o-Y Growth Analysis, By Product Type   

                                5.2.14 Market Attractiveness Analysis, By Product Type

                                5.2.15 Market Share Analysis, By Product Type  

                5.3 Mode of Administration                        

                                5.3.1 Introduction           

                                5.3.2 Intravenous           

                                5.3.3 Oral            

                                5.3.4 Topical      

                                5.3.5 Intra Vesical           

                                5.3.6 Y-o-Y Growth Analysis, By Mode of Administration

                                5.3.7 Market Attractiveness Analysis, By Mode of Administration              

                                5.3.8 Market Share Analysis, By Mode of Administration

                5.3 End users                    

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Clinics        

                                5.3.4 Y-o-Y Growth Analysis, By End users            

                                5.3.5 Market Attractiveness Analysis, By End users           

                                5.3.6 Market Share Analysis, By End users            

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Application

                                                6.1.3.3 By Product Type

                                                6.1.3.4 By Mode of Administration

                                                6.1.3.5 By End users

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Application

                                                6.1.4.3 By Product Type

                                                6.1.4.4 By Mode of Administration

                                                6.1.4.5 By End users

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Application

                                                6.1.5.3 By Product Type

                                                6.1.5.4 By Mode of Administration

                                                6.1.5.6 By End users

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche Ltd                    

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Amgen                         

                8.3 Viralytics                      

                8.4 Novartis Pharmaceuticals Corporation                            

                8.5 Pfizer                            

                8.6 GlaxoSmithKline Pharmaceuticals Limited                     

                8.7 AstraZeneca plc                        

                8.8 Medivation                

                8.9 Advaxis                        

                8.10 Bristol-Myers Squibb                           

                8.11 Merck & Co. and Celgene Corp                        

                8.12 Immunomedics                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. North America Cancer Immunotherapy Market By Application, From 2022 - 2027 (USD Million)
  2. North America Breast Market By Region, From 2022 - 2027 (USD Million)
  3. North America Lung Market By Region, From 2022 - 2027 (USD Million)
  4. North America Melanoma Market By Region, From 2022 - 2027 (USD Million)
  5. North America Colorectal Market By Region, From 2022 - 2027 (USD Million)
  6. North America Head & Neck Market By Region, From 2022 - 2027 (USD Million)
  7. North America Prostate Market By Region, From 2022 - 2027 (USD Million)
  8. North America Cancer Immunotherapy Market By Product Type, From 2022 - 2027 (USD Million)
  9. North America Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Million)
  10. North America Checkpoint inhibitors/immune modulators Market By Region, From 2022 - 2027 (USD Million)
  11. North America Therapeutic cancer vaccines Market By Region, From 2022 - 2027 (USD Million)
  12. North America Oncolytic virus immunotherapy Market By Region, From 2022 - 2027 (USD Million)
  13. North America Cytokines Market By Region, From 2022 - 2027 (USD Million)
  14. North America Adoptive T cell Transfer Market By Region, From 2022 - 2027 (USD Million)
  15. North America Adjuvant immunotherapy Market By Region, From 2022 - 2027 (USD Million)
  16. North America Interferons Market By Region, From 2022 - 2027 (USD Million)
  17. North America Interleukins Market By Region, From 2022 - 2027 (USD Million)
  18. North America BCG Market By Region, From 2022 - 2027 (USD Million)
  19. North America Cancer Immunotherapy Market By Mode of Administration, From 2022 - 2027 (USD Million)
  20. North America Intravenous Market By Region, From 2022 - 2027 (USD Million)
  21. North America Oral Market By Region, From 2022 - 2027 (USD Million)
  22. North America Topical Market By Region, From 2022 - 2027 (USD Million)
  23. North America Intravesical Market By Region, From 2022 - 2027 (USD Million)
  24. North America Cancer Immunotherapy Market By End users, From 2022 - 2027 (USD Million)
  25. North America hospitals Market By Region, From 2022 - 2027 (USD Million)
  26. North America Clinics Market By Region, From 2022 - 2027 (USD Million)
  27. United States Cancer Immunotherapy Market By Application, From 2022 - 2027 (USD Million)
  28. United States Cancer Immunotherapy Market By Product Type, From 2022 - 2027 (USD Million)
  29. United States Cancer Immunotherapy Market By Mode of Administration, From 2022 - 2027 (USD Million)
  30. United States Cancer Immunotherapy Market By End users, From 2022 - 2027 (USD Million)
  31. Canada Cancer Immunotherapy Market By Application, From 2022 - 2027 (USD Million)
  32. Canada Cancer Immunotherapy Market By Product Type, From 2022 - 2027 (USD Million)
  33. Canada Cancer Immunotherapy Market By Mode of Administration, From 2022 - 2027 (USD Million)
  34. Canada Cancer Immunotherapy Market By End users, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample